

FOI 2478

9<sup>th</sup> July 2024**FREEDOM OF INFORMATION ACT 2000 – INFORMATION REQUEST**

---

**Q1. How many patients have been treated for breast cancer (any stage) in the past 3 months with the following systemic anti-cancer therapies:**

- **Abemaciclib + Aromatase Inhibitor (e.g. anastrozole, exemestane, letrozole) - 6**
- **Abemaciclib + Fulvestrant - 1**
- **Alpelisib + Fulvestrant - 0**
- **Anthracycline (e.g. doxorubicin or epirubicin) + Cyclophosphamide - 25**
- **Aromatase Inhibitor as a single agent – not held**
- **Atezolizumab - 1**
- **Capecitabine as a single agent - 6**
- **Carboplatin + Paclitaxel - 3**
- **Eribulin as a single agent or in combination - 1**
- **Everolimus + Exemestane - 0**
- **Fulvestrant as a single agent – not held**
- **Palbociclib + Aromatase Inhibitor (e.g. anastrozole, exemestane, letrozole) - 28**
- **Palbociclib + Fulvestrant - 5**
- **Parp Inhibitors (Olaparib/Talazoparib) - 1**
- **Pembrolizumab - 1**
- **Ribociclib + Aromatase Inhibitor (e.g. anastrozole, exemestane, letrozole) -11**
- **Ribociclib + Fulvestrant - 3**
- **Sacituzumab Govitecan - 3**
- **Taxane (e.g. docetaxel, paclitaxel, nab-paclitaxel) as a single agent - 9**
- **Transtuzumab deruxtecan - 4**
- **Trastuzumab as a single agent or in combination - 36**
- **Trastuzumab emtansine - 6**
- **Any other active systemic anti-cancer therapy - 0**

**Q2. If breast cancer is not treated at or within the Trust, where are patients referred?**

n/a

Email: [Foi.Team@Southerntrust.hscni.net](mailto:Foi.Team@Southerntrust.hscni.net)